摘要 |
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (HusTNFR) and belongs to the gene engineering technology and gene function application field. This invention uses type I or type II long-acting HusTNFR (LHusTNFR) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models. The results showed that LHusTNFR, which has a half-life of 12-140 hours, shows excellent efficacy for preventing the development of severe liver injury on chronic liver disease and for treating early-stage severe liver injury on chronic liver disease. It also significantly reduced the mortality of the model animals. Its efficacy for the prevention and treatment of early-stage severe liver injury on chronic liver disease was significantly better than that of non-LHusTNFR. |